Drugs / GC1118
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02352571 | Jan 2015 → Dec 2016 | colorectal cancer, gastric cancer, metastatic neoplasm | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04077255 | Sep 2019 → Dec 2023 | gastric adenocarcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 2 | NCT03618667 | Jan → Sep 2018 | adult glioblastoma | Samsung Medical Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC1118 | “Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy” NCT04077255 ↗ |
| Action | Inhibit | “GC1118 is a novel monoclonal antibody targeting epidermal growth factor receptor (EGFR) with more potent ligand inhibition than cetuximab or panitumumab.” PMID 31164456 ↗ Jun 2019 |
| Modality | Monoclonal antibody | “a novel monoclonal antibody” PMID 31164456 ↗ Jun 2019 |
| Route | Intravenous | “GC1118 when given by intravenous (IV) infusion” NCT02352571 ↗ |
| Target | EGFR | “targeting epidermal growth factor receptor (EGFR)” PMID 31164456 ↗ Jun 2019 |